Teva gets FDA ok for Pfizer's Accupril

Total annual sales of Accupril in the US, including brand and generic, were about $150 million for the year ended June 30, according to IMS sales data.

By JERUSALEM POST BUSINESS STAFF
August 28, 2007 07:59

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Teva Pharmaceutical Industries Ltd. said Monday the US Food & Drug Administration had approved its Abbreviated New Drug Application to market a generic of Pfizer Inc.'s Accupril hypertension treatment following the expiration of the pediatric exclusivity for the patent. Total annual sales of Accupril in the US, including brand and generic, were about $150 million for the year ended June 30, according to IMS sales data.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS